Mosaic ImmunoEngineering Inc. (CPMV)
USD 1.0
(66.36%)
USD 1.0
(66.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -2.28 Million USD | 34.75% |
| 2021 | -3.5 Million USD | 0.0% |
| 2019 | -733.57 Thousand USD | 0.0% |
| 2017 | -1.04 Million USD | 13.92% |
| 2016 | -1.21 Million USD | 22.83% |
| 2015 | -1.57 Million USD | -9.71% |
| 2014 | -1.43 Million USD | 13.37% |
| 2013 | -1.65 Million USD | -0.31% |
| 2012 | -1.65 Million USD | 56.54% |
| 2011 | -3.8 Million USD | 20.95% |
| 2010 | -4.8 Million USD | 25.43% |
| 2009 | -6.44 Million USD | -272.24% |
| 2008 | 3.74 Million USD | 177.01% |
| 2007 | -4.86 Million USD | 27.48% |
| 2006 | -6.7 Million USD | -176.28% |
| 2005 | 8.79 Million USD | 6065.19% |
| 2004 | 142.57 Thousand USD | 108.74% |
| 2003 | -1.63 Million USD | 25.17% |
| 2002 | -2.18 Million USD | 43.06% |
| 2001 | -3.83 Million USD | 19.42% |
| 2000 | -4.75 Million USD | -348.59% |
| 1999 | 1.91 Million USD | 166.22% |
| 1998 | -2.88 Million USD | -611.18% |
| 1997 | -406.06 Thousand USD | 75.37% |
| 1996 | -1.64 Million USD | -0.54% |
| 1995 | -1.63 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q3 | -311.85 Thousand USD | -4638.05% |
| 2023 Q1 | -382.76 Thousand USD | 23.07% |
| 2023 Q2 | 6872.00 USD | 101.8% |
| 2022 Q4 | -497.54 Thousand USD | -185.63% |
| 2022 Q2 | -883.71 Thousand USD | -21.22% |
| 2022 Q3 | -174.19 Thousand USD | 80.29% |
| 2022 Q1 | -729.02 Thousand USD | 11.63% |
| 2022 FY | - USD | 34.75% |
| 2021 FY | - USD | 0.0% |
| 2021 Q1 | -804.44 Thousand USD | -28.0% |
| 2021 Q2 | -917.62 Thousand USD | -14.07% |
| 2021 Q3 | -961.04 Thousand USD | -4.73% |
| 2021 Q4 | -824.95 Thousand USD | 14.16% |
| 2020 Q4 | -628.46 Thousand USD | -462.09% |
| 2020 Q2 | -101.58 Thousand USD | 2.05% |
| 2020 Q1 | -103.71 Thousand USD | 78.72% |
| 2020 Q3 | -111.8 Thousand USD | -10.06% |
| 2019 Q4 | -487.31 Thousand USD | -60.88% |
| 2019 FY | - USD | 0.0% |
| 2019 Q1 | -158.5 Thousand USD | -10.22% |
| 2019 Q2 | -227.91 Thousand USD | -43.79% |
| 2019 Q3 | -302.91 Thousand USD | -32.91% |
| 2018 Q3 | -203.35 Thousand USD | 13.65% |
| 2018 Q1 | -273.81 Thousand USD | -7.83% |
| 2018 Q2 | -235.51 Thousand USD | 13.99% |
| 2018 Q4 | -143.8 Thousand USD | 29.29% |
| 2017 Q2 | -328.24 Thousand USD | -16.8% |
| 2017 FY | - USD | 13.92% |
| 2017 Q1 | -281.03 Thousand USD | 1.05% |
| 2017 Q3 | -283.09 Thousand USD | 13.75% |
| 2017 Q4 | -253.93 Thousand USD | 10.3% |
| 2016 Q4 | -284.01 Thousand USD | 11.86% |
| 2016 Q3 | -322.22 Thousand USD | 25.2% |
| 2016 Q1 | -404.94 Thousand USD | -18.49% |
| 2016 Q2 | -430.8 Thousand USD | -6.39% |
| 2016 FY | - USD | 22.83% |
| 2015 FY | - USD | -9.71% |
| 2015 Q4 | -341.74 Thousand USD | 14.07% |
| 2015 Q3 | -397.68 Thousand USD | 13.48% |
| 2015 Q2 | -459.65 Thousand USD | -85.92% |
| 2015 Q1 | -247.23 Thousand USD | 30.7% |
| 2014 FY | - USD | 13.37% |
| 2014 Q1 | -378.42 Thousand USD | 55.19% |
| 2014 Q2 | -468.36 Thousand USD | -23.77% |
| 2014 Q3 | -372.15 Thousand USD | 20.54% |
| 2014 Q4 | -356.76 Thousand USD | 4.13% |
| 2013 FY | - USD | -0.31% |
| 2013 Q4 | -844.57 Thousand USD | -139.33% |
| 2013 Q3 | -352.89 Thousand USD | 12.96% |
| 2013 Q2 | -405.43 Thousand USD | -9.36% |
| 2013 Q1 | -370.73 Thousand USD | 13.54% |
| 2012 FY | - USD | 56.54% |
| 2012 Q1 | -683.7 Thousand USD | 31.65% |
| 2012 Q4 | -428.78 Thousand USD | -490.52% |
| 2012 Q2 | -1.37 Million USD | -100.43% |
| 2012 Q3 | 109.79 Thousand USD | 108.01% |
| 2011 Q3 | -1.05 Million USD | 54.23% |
| 2011 Q2 | -2.31 Million USD | -254.74% |
| 2011 Q1 | 1.49 Million USD | 246.26% |
| 2011 FY | - USD | 20.95% |
| 2011 Q4 | -1 Million USD | 5.61% |
| 2010 Q1 | -1.39 Million USD | 38.86% |
| 2010 Q2 | 3.07 Million USD | 320.85% |
| 2010 FY | - USD | 25.43% |
| 2010 Q3 | -2.65 Million USD | -186.28% |
| 2010 Q4 | -1.02 Million USD | 61.4% |
| 2009 Q2 | 7.26 Million USD | 644.38% |
| 2009 Q3 | -2.11 Million USD | -129.15% |
| 2009 Q4 | -2.27 Million USD | -7.42% |
| 2009 FY | - USD | -272.24% |
| 2009 Q1 | -1.33 Million USD | -2.95% |
| 2008 Q1 | -1.3 Million USD | 5.38% |
| 2008 Q3 | -1.14 Million USD | -4948.77% |
| 2008 FY | - USD | 177.01% |
| 2008 Q2 | -22.7 Thousand USD | 98.27% |
| 2008 Q4 | -1.29 Million USD | -13.09% |
| 2007 Q1 | -1.37 Million USD | 19.3% |
| 2007 FY | - USD | 27.48% |
| 2007 Q3 | -1.72 Million USD | -132.12% |
| 2007 Q2 | 5.37 Million USD | 490.11% |
| 2007 Q4 | -1.38 Million USD | 19.83% |
| 2006 Q1 | 59.19 Million USD | 3410.67% |
| 2006 Q3 | -2.69 Million USD | 95.26% |
| 2006 Q2 | -56.82 Million USD | -195.99% |
| 2006 FY | - USD | -176.28% |
| 2006 Q4 | -1.7 Million USD | 36.65% |
| 2005 FY | - USD | 6065.19% |
| 2005 Q2 | -763.64 Thousand USD | -141.76% |
| 2005 Q3 | 8.2 Million USD | 1174.68% |
| 2005 Q1 | 1.82 Million USD | 549.12% |
| 2005 Q4 | -1.78 Million USD | -121.79% |
| 2004 Q2 | -410.64 Thousand USD | -15.52% |
| 2004 Q3 | -515.11 Thousand USD | -25.44% |
| 2004 FY | - USD | 108.74% |
| 2004 Q1 | -355.49 Thousand USD | 12.06% |
| 2004 Q4 | -407.11 Thousand USD | 20.97% |
| 2003 Q3 | -461.7 Thousand USD | -10.63% |
| 2003 Q2 | -417.34 Thousand USD | 10.12% |
| 2003 Q1 | -464.31 Thousand USD | 32.87% |
| 2003 FY | - USD | 25.17% |
| 2003 Q4 | -404.22 Thousand USD | 12.45% |
| 2002 Q1 | -905.98 Thousand USD | 26.42% |
| 2002 FY | - USD | 43.06% |
| 2002 Q4 | -691.66 Thousand USD | -13.81% |
| 2002 Q3 | -607.71 Thousand USD | 14.9% |
| 2002 Q2 | -714.11 Thousand USD | 21.18% |
| 2001 FY | - USD | 19.42% |
| 2001 Q1 | -1.29 Million USD | -12.77% |
| 2001 Q4 | -1.23 Million USD | -25.75% |
| 2001 Q3 | -979.11 Thousand USD | 33.24% |
| 2001 Q2 | -1.46 Million USD | -13.23% |
| 2000 FY | - USD | -348.59% |
| 2000 Q4 | -1.14 Million USD | -36.2% |
| 2000 Q3 | -843.27 Thousand USD | -419.36% |
| 2000 Q1 | 2.95 Million USD | 773.64% |
| 2000 Q2 | 264.05 Thousand USD | -91.06% |
| 1999 Q4 | -438.39 Thousand USD | 49.41% |
| 1999 Q3 | -866.62 Thousand USD | 0.0% |
| 1999 FY | - USD | 166.22% |
| 1998 FY | - USD | -611.18% |
| 1997 FY | - USD | 75.37% |
| 1996 FY | - USD | -0.54% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.784% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 61.469% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.438% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 86.848% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.429% |
| Mesoblast Limited | -62.38 Million USD | 96.338% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -48.725% |
| Genus plc | 73.7 Million USD | 103.1% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 65.447% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 35.594% |
| Marizyme, Inc. | -34.28 Million USD | 93.336% |
| ContraFect Corporation | -64.99 Million USD | 96.485% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 73.957% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 49.527% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -62.967% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 13.612% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 1.693% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -340.982% |
| Accustem Sciences Inc. | -3.74 Million USD | 39.022% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 95.263% |
| EV Biologics, Inc. | -1.26 Million USD | -80.288% |
| Q BioMed Inc. | -617.62 Thousand USD | -269.881% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 163.955% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -261.238% |
| Biomind Labs Inc. | -1.03 Million USD | -120.82% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 123.129% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 68.099% |
| Skye Bioscience, Inc. | -13.54 Million USD | 83.137% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -53.588% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9037.956% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 41.187% |
| IMV Inc. | -35.52 Million USD | 93.569% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 85.605% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 8.692% |
| GB Sciences, Inc. | -1.41 Million USD | -60.893% |
| Alpha Cognition Inc. | -9.7 Million USD | 76.462% |
| HST Global, Inc. | -5303.00 USD | -42979.182% |
| CSL Limited | 4.78 Billion USD | 100.048% |
| Halberd Corporation | -74.27 Thousand USD | -2975.552% |
| Enzolytics Inc. | -2.12 Million USD | -7.656% |
| Resverlogix Corp. | -11.74 Million USD | 80.544% |
| Affymax, Inc. | -14.29 Million USD | 84.019% |
| SYBLEU INC | -141.57 Thousand USD | -1513.67% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 25.417% |
| argenx SE | -216.02 Million USD | 98.942% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.872% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 287.715% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -52.41% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 703.016% |
| AVAX Technologies, Inc. | -6.11 Million USD | 62.627% |
| Zenith Capital Corp. | -8.6 Million USD | 73.455% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.081% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -13013.421% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 6.621% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1197.825% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 94.236% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 21.016% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -118.337% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 34075.149% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -30.542% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -18.927% |
| BioStem Technologies, Inc. | -7.55 Million USD | 69.756% |
| ONE Bio Corp. | 13.61 Million USD | 116.782% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1161.535% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -11.059% |
| Agentix Corp. | -1.37 Million USD | -66.538% |
| LadRx Corporation | 412.28 Thousand USD | 654.107% |
| Cell Source, Inc. | -4.27 Million USD | 46.531% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -522.102% |
| Regen BioPharma, Inc. | 1.46 Million USD | 255.836% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -143.822% |
| NovAccess Global Inc. | -1.03 Million USD | -120.767% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 125.802% |
| Itoco Inc. | -1.86 Million USD | -22.231% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -501.783% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -104.703% |
| Kadimastem Ltd | -2.62 Million USD | 12.951% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -855.254% |
| CytoDyn Inc. | -18.02 Million USD | 87.329% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -2790.697% |
| Mobile Lads Corp. | -2.24 Million USD | -1.933% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -18580.914% |
| Qrons Inc. | -40.08 Thousand USD | -5599.681% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -370.371% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 533.133% |
| Rebus Holdings, Inc. | -951 Thousand USD | -140.22% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -115.11% |
| International Stem Cell Corporation | 202 Thousand USD | 1230.935% |
| Bioxytran, Inc. | -3.82 Million USD | 40.199% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4239.835% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 7.207% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.631% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -4976.642% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 16.564% |
| Neutra Corp. | -181.24 Thousand USD | -1160.429% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 88.668% |
| PureTech Health plc | -11.62 Million USD | 80.352% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 88.667% |
| IXICO plc | -707 Thousand USD | -223.124% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 70.273% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 95.275% |
| CSL Limited | 4.73 Billion USD | 100.048% |
| Cellectis S.A. | -92.63 Million USD | 97.534% |